What is the malignant nature of human ductal carcinoma in situ?

Nature Reviews Cancer

Volumn 11, Issue 1, 2011, Pages 68-75

  Espina, Virginia ^a   Liotta, Lance A ^a  

^a GEORGE MASON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS; AUTOPHAGY; CANCER GROWTH; CANCER STAGING; CANCER STEM CELL; CELL STRESS; CELL SURVIVAL; GENETIC STABILITY; HUMAN; HYPOXIA; INTRADUCTAL CARCINOMA; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW;

ANIMALS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; DISEASE PROGRESSION; FEMALE; HUMANS; MICE;

EID: 78650599928     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc2950     Document Type: Review

References (106)

1. Allegra, C. et al. NIH state of the science conference statement: diagnosis and management of ductal carcinoma in situ. NIH Consens. State Sci. Statements 26, 1-27 (2009).
2. Castro, N. P. et al. Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma. Breast Cancer Res. 10, R87 (2008).
3. Damonte, P. et al. Mammary carcinoma behavior is programmed in the precancer stem cell. Breast Cancer Res. 10, R50 (2008).
4. Espina, V. et al. Malignant precursor cells preexist in human breast DCIS and require autophagy for survival. PLoS ONE 5, e10240 (2010).
5. Ma, X. J., Dahiya, S., Richardson, E., Erlander, M. & Sgroi, D. C. Gene expression profiling of the tumor microenvironment during breast cancer progression. Breast Cancer Res. 11, R7 (2009).
6. Ma, X. J. et al. Gene expression profiles of human breast cancer progression. Proc. Natl Acad. Sci. USA 100, 5974-5979 (2003).
7. Namba, R. et al. Heterogeneity of mammary lesions represent molecular differences. BMC Cancer 6, 275 (2006).
8. Sgroi, D. C. Preinvasive breast cancer. Annu. Rev. Pathol. 5, 193-221 (2010).
9. Fordyce, C. et al. DNA damage drives an activin a dependent induction of cyclooxygenase 2 in premalignant cells and lesions. Cancer Prev. Res. (Phila) 3, 190-201 (2010).
10. Gauthier, M. L. et al. Abrogated response to cellular stress identifies DCIS associated with subsequent tumor events and defines basal like breast tumors. Cancer Cell 12, 479-491 (2007).
11. Mathew, R., Karantza Wadsworth, V. & White, E. Role of autophagy in cancer. Nature Rev. Cancer 7, 961-967 (2007).
12. Sendoel, A., Kohler, I., Fellmann, C., Lowe, S. W. & Hengartner, M. O. HIF 1 antagonizes p53 mediated apoptosis through a secreted neuronal tyrosinase. Nature 465, 577-583 (2010).
13. Boecker, W. Preneoplasia of the Breast (Elsevier GmbH, Munich, 2006).
14. Gudjonsson, T., Adriance, M. C., Sternlicht, M. D., Petersen, O. W. & Bissell, M. J. Myoepithelial cells: their origin and function in breast morphogenesis and neoplasia. J. Mammary Gland Biol. Neoplasia 10, 261-272 (2005).
15. Tavassoli, F. in Tumors of the Breast and Female Genital Organs (eds Tavassoli, F. & Devilee, P. ) 63-73 (IARC Press, Lyon, 2003).
16. Claus, E. B. et al. Pathobiologic findings in DCIS of the breast: morphologic features, angiogenesis, HER 2/ neu and hormone receptors. Exp. Mol. Pathol. 70, 303-316 (2001).
17. Hu, M. et al. Regulation of in situ to invasive breast carcinoma transition. Cancer Cell 13, 394-406 (2008).
18. Page, D. L., Dupont, W. D., Rogers, L. W. & Landenberger, M. Intraductal carcinoma of the breast: follow up after biopsy only. Cancer 49, 751-758 (1982).
19. Betsill, W. L., Rosen, P. P., Lieberman, P. H. & Robbins, G. F. Intraductal carcinoma. Long term follow up after treatment by biopsy alone. JAMA 239, 1863-1867 (1978).
20. Collins, L. C. et al. Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsy: results from the Nurses' Health Study. Cancer 103, 1778-1784 (2005).
21. Fisher, B. et al. Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience. Semin. Oncol. 28, 400-418 (2001). (Pubitemid 32762083)
22. Berman, H. K., Gauthier, M. L. & Tlsty, T. D. Premalignant breast neoplasia: a paradigm of interlesional and intralesional molecular heterogeneity and its biological and clinical ramifications. Cancer Prev. Res. (Phila) 3, 579-587 (2010).
23. Lagios, M. D. Heterogeneity of duct carcinoma in situ (DCIS): relationship of grade and subtype analysis to local recurrence and risk of invasive transformation. Cancer Lett. 90, 97-102 (1995).
24. Bussolati, G., Bongiovanni, M., Cassoni, P. & Sapino, A. Assessment of necrosis and hypoxia in ductal carcinoma in situ of the breast: basis for a new classification. Virchows Arch. 437, 360-364 (2000).
25. Bindra, R. S. & Glazer, P. M. Genetic instability and the tumor microenvironment: towards the concept of microenvironment induced mutagenesis. Mutat. Res. 569, 75-85 (2005).
26. Kongara, S. et al. Autophagy regulates keratin 8 homeostasis in mammary epithelial cells and in breast tumors. Mol. Cancer Res. 8, 873-884 (2010).
27. Li, C. Y. et al. Persistent genetic instability in cancer cells induced by non DNA damaging stress exposures. Cancer Res. 61, 428-432 (2001).
28. Mathew, R., Karantza Wadsworth, V. & White, E. Assessing metabolic stress and autophagy status in epithelial tumors. Meth. Enzymol. 453, 53-81 (2009).
29. Nelson, D. A. et al. Hypoxia and defective apoptosis drive genomic instability and tumorigenesis. Genes Dev. 18, 2095-2107 (2004).
30. Vakkila, J. & Lotze, M. T. Inflammation and necrosis promote tumour growth. Nature Rev. Immunol. 4, 641-648 (2004).
31. Paweletz, C. P. et al. Reverse phase protein microarrays which capture disease progression show activation of prosurvival pathways at the cancer invasion front. Oncogene 20, 1981-1989 (2001).
32. Klionsky, D. J. et al. Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy 4, 151-175 (2008).
33. Levine, B. & Ranganathan, R. Autophagy: Snapshot of the network. Nature 466, 38-40 (2010).
34. Lyng, H., Sundfor, K., Trope, C. & Rofstad, E. K. Oxygen tension and vascular density in human cervix carcinoma. Br. J. Cancer 74, 1559-1563 (1996).
35. Vaupel, P., Kallinowski, F. & Okunieff, P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res. 49, 6449-6465 (1989).
36. Boyer, M. J., Barnard, M., Hedley, D. W. & Tannock, I. F. Regulation of intracellular pH in subpopulations of cells derived from spheroids and solid tumours. Br. J. Cancer 68, 890-897 (1993).
37. Mayr, N. A., Staples, J. J., Robinson, R. A., Vanmetre, J. E. & Hussey, D. H. Morphometric studies in intraductal breast carcinoma using computerized image analysis. Cancer 67, 2805-2812 (1991).
38. Pinder, S. E. Ductal carcinoma in situ (DCIS): pathological features, differential diagnosis, prognostic factors and specimen evaluation. Mod. Pathol. 23 (Suppl. 2), S8-S13 (2010).
39. Mihaylova, V. T. et al. Decreased expression of the DNA mismatch repair gene Mlh1 under hypoxic stress in mammalian cells. Mol. Cell. Biol. 23, 3265-3273 (2003).
40. Young, S. D., Marshall, R. S. & Hill, R. P. Hypoxia induces DNA overreplication and enhances metastatic potential of murine tumor cells. Proc. Natl Acad. Sci. USA 85, 9533-9537 (1988).
41. Rotin, D., Robinson, B. & Tannock, I. F. Influence of hypoxia and an acidic environment on the metabolism and viability of cultured cells: potential implications for cell death in tumors. Cancer Res. 46, 2821-2826 (1986).
42. Tannock, I. F. & Kopelyan, I. Influence of glucose concentration on growth and formation of necrosis in spheroids derived from a human bladder cancer cell line. Cancer Res. 46, 3105-3110 (1986).
43. Primeau, A. J., Rendon, A., Hedley, D., Lilge, L. & Tannock, I. F. The distribution of the anticancer drug Doxorubicin in relation to blood vessels in solid tumors. Clin. Cancer Res. 11, 8782-8788 (2005).
44. Jin, S., DiPaola, R. S., Mathew, R. & White, E. Metabolic catastrophe as a means to cancer cell death. J. Cell Sci. 120, 379-383 (2007).
45. Tang, D. et al. Endogenous HMGB1 regulates autophagy. J. Cell Biol. 190, 881-892 (2010).
46. Shimizu, S. et al. Role of Bcl 2 family proteins in a non apoptotic programmed cell death dependent on autophagy genes. Nature Cell Biol. 6, 1221-1228 (2004).
47. Hockel, M. & Vaupel, P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J. Natl Cancer Inst. 93, 266-276 (2001).
48. Yu, F., White, S. B., Zhao, Q. & Lee, F. S. HIF 1α binding to VHL is regulated by stimulus sensitive proline hydroxylation. Proc. Natl Acad. Sci. USA 98, 9630-9635 (2001).
49. Semenza, G. L. Targeting HIF 1 for cancer therapy. Nature Rev. Cancer 3, 721-732 (2003).
50. Cuvier, C., Jang, A. & Hill, R. P. Exposure to hypoxia, glucose starvation and acidosis: effect on invasive capacity of murine tumor cells and correlation with cathepsin (L + B) secretion. Clin. Exp. Metastasis 15, 19-25 (1997).
51. Young, S. D. & Hill, R. P. Effects of reoxygenation on cells from hypoxic regions of solid tumors: anticancer drug sensitivity and metastatic potential. J. Natl Cancer Inst. 82, 371-380 (1990).
52. McDermott, K. M. et al. p16(INK4a) prevents centrosome dysfunction and genomic instability in primary cells. PLoS Biol. 4, e51 (2006).
53. Bracken, A. P. et al. EZH2 is downstream of the pRB E2F pathway, essential for proliferation and amplified in cancer. EMBO J. 22, 5323-5335 (2003).
54. Reynolds, P. A. et al. Tumor suppressor p16INK14A regulates polycomb mediated DNA hypermethylation in human mammary epithelial cells. J. Biol. Chem. 281, 24790-24802 (2006).
55. Ding, L., Erdmann, C., Chinnaiyan, A. M., Merajver, S. D. & Kleer, C. G. Identification of EZH2 as a molecular marker for a precancerous state in morphologically normal breast tissues. Cancer Res. 66, 4095-4099 (2006).
56. Kleer, C. G. et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc. Natl Acad. Sci. USA 100, 11606-11611 (2003).
57. Crawford, Y. G. et al. Histologically normal human mammary epithelia with silenced p16(INK4a) overexpress COX 2, promoting a premalignant program. Cancer Cell 5, 263-273 (2004).
58. Kerlikowske, K. et al. Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. J. Natl Cancer Inst. 102, 627-637 (2010).
59. Simpson, P. T., Reis Filho, J. S., Gale, T. & Lakhani, S. R. Molecular evolution of breast cancer. J. Pathol. 205, 248-254 (2005).
60. Stingl, J. & Caldas, C. Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis. Nature Rev. Cancer 7, 791-799 (2007).
61. Burkhardt, L. et al. Gene amplification in ductal carcinoma in situ of the breast. Breast Cancer Res. Treat 123, 757-765 (2010).
62. Li, H. et al. PIK3CA mutations mostly begin to develop in ductal carcinoma of the breast. Exp. Mol. Pathol. 88, 150-155 (2010).
63. Bocker, W. et al. Common adult stem cells in the human breast give rise to glandular and myoepithelial cell lineages: a new cell biological concept. Lab. Invest. 82, 737-746 (2002).
64. Al Hajj, M., Wicha, M. S., Benito Hernandez, A., Morrison, S. J. & Clarke, M. F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl Acad. Sci. USA 100, 3983-3988 (2003).
65. Boecker, W. et al. Usual ductal hyperplasia of the breast is a committed stem (progenitor) cell lesion distinct from atypical ductal hyperplasia and ductal carcinoma in situ. J. Pathol. 198, 458-467 (2002).
66. Liotta, L. A. et al. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 284, 67-68 (1980).
67. Witkiewicz, A. K. et al. An absence of stromal caveolin 1 expression predicts early tumor recurrence and poor clinical outcome in human breast cancers. Am. J. Pathol. 174, 2023-2034 (2009).
68. Chen, L. et al. Precancerous stem cells have the potential for both benign and malignant differentiation. PLoS ONE 2, e293 (2007).
69. Tlsty, T. Cancer: whispering sweet somethings. Nature 453, 604-605 (2008).
70. Levine, B. & Abrams, J. p53: the Janus of autophagy? Nature Cell Biol. 10, 637-639 (2008).
71. Qu, X. et al. Autophagy gene dependent clearance of apoptotic cells during embryonic development. Cell 128, 931-946 (2007).
72. Samaddar, J. S. et al. A role for macroautophagy in protection against 4 hydroxytamoxifen induced cell death and the development of antiestrogen resistance. Mol. Cancer Ther. 7, 2977-2987 (2008).
73. Vazquez Martin, A., Oliveras Ferraros, C. & Menendez, J. A. Autophagy facilitates the development of breast cancer resistance to the anti HER2 monoclonal antibody trastuzumab. PLoS ONE 4, e6251 (2009).
74. White, E. & DiPaola, R. S. The double edged sword of autophagy modulation in cancer. Clin. Cancer Res. 15, 5308-5316 (2009).
75. Amaravadi, R. K. et al. Autophagy inhibition enhances therapy induced apoptosis in a Myc induced model of lymphoma. J. Clin. Invest. 11 7, 326-336 (2007).
76. Bellodi, C. et al. Targeting autophagy potentiates tyrosine kinase inhibitor induced cell death in Philadelphia chromosome positive cells, including primary CML stem cells. J. Clin. Invest. 11 9, 1109-1123 (2009).
77. Hoyer Hansen, M. & Jaattela, M. Autophagy: an emerging target for cancer therapy. Autophagy 4, 574-580 (2008).
78. Ostenfeld, M. S. et al. Anti cancer agent siramesine is a lysosomotropic detergent that induces cytoprotective autophagosome accumulation. Autophagy 4, 487-499 (2008).
79. Schoenlein, P. V., Periyasamy Thandavan, S., Samaddar, J. S., Jackson, W. H. & Barrett, J. T. Autophagy facilitates the progression of ERα positive breast cancer cells to antiestrogen resistance. Autophagy 5, 400-403 (2009).
80. Behrends, C., Sowa, M. E., Gygi, S. P. & Harper, J. W. Network organization of the human autophagy system. Nature 466, 68-76 (2010).
81. McPhee, C. K., Logan, M. A., Freeman, M. R. & Baehrecke, E. H. Activation of autophagy during cell death requires the engulfment receptor Draper. Nature 465, 1093-1096 (2010).
82. Yu, L. et al. Termination of autophagy and reformation of lysosomes regulated by mTOR. Nature 465, 942-946 (2010).
83. Fung, C., Lock, R., Gao, S., Salas, E. & Debnath, J. Induction of autophagy during extracellular matrix detachment promotes cell survival. Mol. Biol. Cell 19, 797-806 (2008).
84. Evans, A. et al. Lesion size is a major determinant of the mammographic features of ductal carcinoma in situ: findings from the Sloane project. Clin. Radiol. 65, 181-184 (2010).
85. Evans, A. J. et al. Screening detected and symptomatic ductal carcinoma in situ: mammographic features with pathologic correlation. Radiology 191, 237-240 (1994).
86. Holland, R. et al. Extent, distribution, and mammographic/histological correlations of breast ductal carcinoma in situ. Lancet 335, 519-522 (1990).
87. Stomper, P. C. & Connolly, J. L. Ductal carcinoma in situ of the breast: correlation between mammographic calcification and tumor subtype. AJR Am. J. Roentgenol. 159, 483-485 (1992).
88. Evans, A. J. et al. Correlations between the mammographic features of ductal carcinoma in situ (DCIS) and C erbB 2 oncogene expression. Nottingham Breast Team. Clin. Radiol. 49, 559-562 (1994).
89. Hermann, G. et al. Mammographic pattern of microcalcifications in the preoperative diagnosis of comedo ductal carcinoma in situ: histopathologic correlation. Can. Assoc. Radiol. J. 50, 235-240 (1999).
90. Gao, W., Ding, W. X., Stolz, D. B. & Yin, X. M. Induction of macroautophagy by exogenously introduced calcium. Autophagy 4, 754-761 (2008).
91. Ducharme, J. & Farinotti, R. Clinical pharmacokinetics and metabolism of chloroquine. Focus on recent advancements. Clin. Pharmacokinet. 31, 257-274 (1996).
92. Loehberg, C. R. et al. Ataxia telangiectasia mutated and p53 are potential mediators of chloroquine induced resistance to mammary carcinogenesis. Cancer Res. 67, 12026-12033 (2007).
93. Rahim, R. & Strobl, J. S. Hydroxychloroquine, chloroquine, and all trans retinoic acid regulate growth, survival, and histone acetylation in breast cancer cells. Anticancer Drugs 20, 736-745 (2009).
94. Savarino, A., Lucia, M. B., Giordano, F. & Cauda, R. Risks and benefits of chloroquine use in anticancer strategies. Lancet Oncol. 7, 792-793 (2006).
95. Wozniacka, A., Cygankiewicz, I., Chudzik, M., Sysa Jedrzejowska, A. & Wranicz, J. K. The cardiac safety of chloroquine phosphate treatment in patients with systemic lupus erythematosus: the influence on arrhythmia, heart rate variability and repolarization parameters. Lupus 15, 521-525 (2006).
96. Maclean, K. H., Dorsey, F. C., Cleveland, J. L. & Kastan, M. B. Targeting lysosomal degradation induces p53 dependent cell death and prevents cancer in mouse models of lymphomagenesis. J. Clin. Invest. 11 8, 79-88 (2008).
97. Fisher, B. et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P 1 study. J. Natl Cancer Inst. 97, 1652-1662 (2005).
98. Vogel, V. G. The NSABP Study of Tamoxifen and Raloxifene (STAR) trial. Expert Rev. Anticancer Ther. 9, 51-60 (2009).
99. Fisher, B. et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P 1 Study. J. Natl Cancer Inst. 90, 1371-1388 (1998).
100. Kelloff, G. J. & Sigman, C. C. Assessing intraepithelial neoplasia and drug safety in cancer preventive drug development. Nature Rev. Cancer 7, 508-518 (2007).
101. O'Shaughnessy, J. A. et al. Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Clin. Cancer Res. 8, 314-346 (2002).
102. Hwang, E. S. et al. Ductal carcinoma in situ in BRCA mutation carriers. J. Clin. Oncol. 25, 642-647 (2007).
103. Kwong, A. et al. Clinical and pathological characteristics of Chinese patients with BRCA related breast cancer. Hugo J. 3, 63-76 (2009).
104. Smith, K. L. et al. BRCA mutations in women with ductal carcinoma in situ. Clin. Cancer Res. 13, 4306-4310 (2007).
105. Arun, B. et al. High prevalence of preinvasive lesions adjacent to BRCA1/2 associated breast cancers. Cancer Prev. Res. (Phila) 2, 122-127 (2009).
106. Deng, C. X. & Scott, F. Role of the tumor suppressor gene Brca1 in genetic stability and mammary gland tumor formation. Oncogene 19, 1059-1064 (2000).